Pharmala Biotech Holdings Inc. (MDMA.CN)
| Previous Close | 0.0400 |
| Open | 0.0000 |
| Bid | 0.0700 x N/A |
| Ask | 0.0750 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 475,025 |
| Market Cap | 6.225M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
PharmAla Biotech is the only company in the world with the ability to ship GMP MDMA and Psilocybin today For customers looking to take advantage of the new TGA guidance, please see PharmAla's webinar on the regulations surrounding the shipment of these molecules across international borders. PharmAla stands ready to provide regulated psychiatrists with these materials today. VANCOUVER, British Columbia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) appl
- ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News
The Power Play by The Market Herald has announced the release of new interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia discussing their latest news.
- GlobeNewswire
PharmAla Biotech granted an Export Permit for 300 grams of LaNeo™ MDMA
PharmAla Biotech believes that this is the largest export permit of MDMA granted to date by Health CanadaVANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules (including MDMA) and its manufacturing partners have received an export permit for 300 grams of its LaNeo™ MDMA. PharmAla believes this is the largest single Health Canada
